Search Results
Your search for ,twO matches 12004 pages
Showing 8651 - 8700Neural Stem Cell Transplantation May Improve Cognitive Function in Brain Cancer
The potentially devastating long-term consequences on cognitive function in patients with brain cancer following cranial irradiation led Charles L. Limoli, PhD, Professor of Radiation Oncology, University of California, Irvine, to study neural stem cell transplantation and how the procedure may...
Evidence of Improved Survival for Lobectomy vs Limited Resection in Early-stage Lung Cancer
“Evidence is statistically inconclusive but suggestive that lobectomy, compared with limited resection, is associated with increased long-term survival for early-stage lung cancer,” according to a study reported in the Journal of the National Cancer Institute. The study analyzed data from 679...
Significant Neurologic and Executive Function Impairment among Breast Cancer Survivors
Women who survive breast cancer show significant neurologic impairment, with outcomes appearing to be significantly poorer for those treated with chemotherapy, according to a report in the Archives of Neurology. Investigators at Stanford University School of Medicine in California conducted an...
The Art and Grace of Just Letting Go
Like a breeze rippling across a lake, the end of your career is approaching and you cannot escape its path. You can see it coming, and before you know it the inexorable movement will rush past you. You have two choices: Build a sail so that you can capture the energy and move with it, or remain...
Researchers Find Remarkable Heterogeneity in Sarcomas
Does one size fit all for the treatment of sarcoma? The answer is a resounding “no,” according to Jean-Yves Blay, MD, Department of Medicine, Université Claude Bernard, and Unité INSERM (National Institute of Health and Medical Research Unit), Lyon, France. Researchers have been able to classify...
SIDEBAR: Patient Advocates Form Huge Presence at EMCC 2011
Patient advocate and two-time breast cancer survivor Kathi Apostolidis from Greece spoke at a session on patients’ and physicians’ use of social media. “Social media is not a fad. It has real value,” she said. She uses social media to connect with oncologists and policymakers across the globe, and...
FDA Approves First Drug to Treat Myelofibrosis
The FDA has approved ruxolitinib (Jakafi), the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis. Myelofibrosis is a disease in which the bone marrow is replaced by scar tissue resulting in blood cells being made in organs such as the liver and the...
Clinical Cancer Advances 2011: ASCO’s Report on Progress Against Cancer
This year marks the 40th anniversary ofthe National Cancer Act and places a more prominent focus on how much progress against cancer has been made over the past 4 decades. In the past year alone, significant advances have been made in cancer prevention and screening, hard-to-treat cancers, and...
Lessons from a Northern Neighbor: A Conversation with Joseph M. Connors, MD
Policy analysts searching for a better understanding of health-care models often compare the cancer delivery systems of Canada and the United States. The ASCO Post recently spoke with Joseph M. Connors, MD, Clinical Professor and Director of the BC Cancer Agency’s Centre for Lymphoid Cancer,...
Gathering Data Point to Potential Advantages of Vismodegib in Basal Cell Carcinoma and Other Advanced Cancers
Vismodegib is a small-molecule, orally active hedgehog pathway inhibitor that has shown considerable promise in treating basal cell carcinoma and is currently being evaluated alone and in combination in early-phase trials in medulloblastoma and a long list of other cancers.1 Owing to its...
Expert Point of View: Benefit of Panitumumab Seen Primarily in Patients with Recurrent or Metastatic Head and Neck Cancer and HPV-negative Tumors
Discussing the presentation, Jean Bourhis, MD, PhD, of the Institut Gustave Roussy in Villejuif, France, said that while HPV has become a major prognostic factor in locally advanced head and neck cancer, its prognostic value in recurrent and metastatic disease is less clear. “The role of HPV in...
Important Briefs from the 2011 European Multidisciplinary Cancer Congress
Nearly 16,000 people from 16 countries attended this year’s European Multidisciplinary Cancer Congress, held recently in Stockholm. The ASCO Post has featured several key reports from the meeting and will offer further coverage in upcoming issues. Additional noteworthy studies presented at the...
ASH Honors Janet Rowley, MD, and Brian Druker, MD
The American Society of Hematology (ASH) recognized Janet Rowley, MD, of the University of Chicago Medical Center, and Brian Druker, MD, of Oregon Health & Science University with the 2011 Ernest Beutler Lecture and Prize for their significant advances in the diagnosis and treatment of chronic...
How Should We Treat Nodular Lymphocyte-predominant Hodgkin Lymphoma?
At the 2011 Pan-Pacific Lymphoma Conference in Kauai, Hawaii, Andreas Engert, MD, Chairman of the German Hodgkin Lymphoma Study Group (GHSG) and Professor of Medicine at the University Hospital of Cologne, Germany, discussed the treatment of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL),...
2011 in Review: Oncology Drugs/Indications Newly Approved by FDA
At press time, the FDA had granted approval for the following new agents and indications for cancer treatment in 2011. Asparaginase Erwinia chrysanthemi (Erwinaze) as a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in patients who have...
SIDEBAR: Adding Trastuzumab to Adjuvant Chemotherapy
Adding trastuzumab (Herceptin) to adjuvant chemotherapy significantly improved disease-free survival of patients with resected stage I to III invasive HER2-positive breast cancer in the phase III North Central Cancer Treatment Group (NCCTG) N9831 trial. There was also a trend toward a further...
Prostate Cancer Screening Reconsidered
Prostate cancer is the most prevalent nonskin cancer in men. An estimated 16% of men are diagnosed with prostate cancer, yet only 3% of men die from it.1 Unlike other cancers, prostate cancer is associated with a prolonged lead-time, meaning it can take anywhere from 5 to 12 years to become...
A Conversation with Ezekiel J. Emanuel, MD, PhD
Last September, Ezekiel J. Emanuel, MD, PhD, a leading scholar in bioethics and health-care policy, was named the Diane v.S. Levy and Robert M. Levy University Professor and Vice Provost for Global Initiatives at the University of Pennsylvania in Philadelphia. His appointment will be shared between ...
Adjuvant Chemotherapy with S-1 Improves Survival in Stage II/III Gastric Cancer
Postoperative adjuvant therapy with the oral fluoropyrimidine derivative S-1 improved overall survival and relapse-free survival in patients with stage II or III gastric cancer who had D2 gastrectomy. Five-year survival rates in the phase III study were 71.7% for patients in the S-1 group vs 61.1%...
ASCO President Michael P. Link, MD, Joins Colleagues in Honoring a Friend and Touching the Future through Philanthropy
As an active member of ASCO, and as a leader of the Society in recent years, ASCO President Michael P. Link, MD, has a long history of giving to the Society-affiliated Conquer Cancer Foundation. “Our family has always felt that it’s a good thing to support,” he said. “The Foundation supports...
Young Investigator Award Renamed to Honor ASCO Founder Jane C. Wright, MD
At the 2011 Annual Meeting, the Conquer Cancer Foundation renamed one of its annual awards to honor the legacy of one of ASCO’s groundbreaking founders. The Jane C. Wright, MD, Young Investigator Award (YIA) recognizes Dr. Wright’s leadership at ASCO, her contributions to the field of oncology, and ...
Weekly Online Polls Help Define Key Concerns of ASCO Members
ASCO members now have the opportunity to help the Society gather information and opinions about important cancer policy issues. ASCO in Action, ASCO’s revamped policy news website (http://ascoaction.asco.org), features weekly polls designed to gauge the views of ASCO members on a variety of topics ...
Conquer Cancer Foundation Programs for Medical Students and Residents Support Diversity in Oncology Workforce
The Conquer Cancer Foundation funds two programs, the Medical Student Rotation (MSR) and the Resident Travel Award (RTA), to facilitate the recruitment and retention of individuals from populations underrepresented in medicine to cancer careers, with a special focus on the development of clinical...
Gastric Cancer Is on the Rise: Screening and Education Are Vital
Gastric cancer is diagnosed in nearly 1 million people globally each year and is responsible for 740,000 deaths, making it the second leading cause of cancer death in the world. According to the American Cancer Society, more than 21,000 people in the United States were diagnosed with gastric...
Update on Novel Treatments for Peripheral T-cell Lymphoma
At the recent Pan-Pacific Lymphoma Conference in Kauai, Hawaii, Julie M. Vose, MD, from the University of Nebraska Medical Center, Omaha, discussed novel treatments for peripheral T-cell lymphoma (PTCL). PTCL is a heterogeneous group of aggressive T-cell/natural killer (NK) cell non-Hodgkin...
Advances in Lung Cancer Treatment Show Incremental Benefits, but Room for Improvement Remains
Newer therapies for the treatment of non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) were discussed at the Chemotherapy Foundation Symposium. More inroads have been made in improving outcomes for patients with NSCLC than for those with SCLC, but there is still room for...
Highlights of Bladder Cancer Research Include Novel Agents and New Approach to Identifying Biomarkers
It is an exciting time for researchers involved in developing new therapies for bladder cancer. More agents are in clinical development, drugs with novel mechanisms and novel trial designs are being implemented, and functional collaboration is occurring in the field, according to Noah Hahn, MD,...
CLEOPATRA Trial Finds Dual HER2 Blockade Improves Progression-free Survival in Advanced Breast Cancer
Women with HER2-positive advanced breast cancer are much less likely to have disease progression or die when two agents are used instead of one to target the HER2 signaling pathway, investigators for the international phase III CLEOPATRA trial found. The 808 women studied were randomly assigned to...
Presurgical Gemcitabine/Cisplatin Improves Survival in Lung Cancer
Preoperative gemcitabine plus cisplatin had a statistically significant impact on outcomes among patients with stage IIB/IIIA non–small-cell lung cancer in a phase III randomized study comparing surgery alone or surgery plus preoperative chemotherapy. The 3-year progression-free survival rates were ...
Integrative Oncology: Essential to Cancer Care
During the 1960s and 1970s, the concept of an expanded approach to oncologic treatment encompassing “body, mind, and spirit” grew in patient popularity and morphed into two basic categories: “alternative” and “complementary” therapies. Together, these later became known by the acronym CAM, for...
Ruxolitinib for Myelofibrosis Therapy: A Good Start but a Long Road Ahead
Following a priority review process for orphan diseases, ruxolitinb (Jakafi) recently became the first drug to receive FDA approval for the treatment of intermediate- and high-risk myelofibrosis. Discovery in 2004 of the JAK2V617F mutation in a significant proportion of patients with...
Don’t Take Away Our Hope
After experiencing the loss of my wife Dina’s first pregnancy during her second trimester, we naturally worried that something would go wrong when she became pregnant again. But when our son Will was delivered at full term, we thought we could finally relax. Born at a whopping 10 lb, Will seemed...
Adding Alemtuzumab to Fludarabine in CLL
In a randomized phase III trial among previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), the combination of alemtuzumab (Campath) plus fludarabine resulted in significant improvements in progression-free survival, complete response rate, and overall survival ...
SIDEBAR: Clinical Trials of VTE Prophylaxis for Outpatients
Several studies are investigating low-molecular-weight heparins to reduce the risk of venous thromboembolism (VTE) among patients with cancer. “I enrolled patients in SAVE-ONCO,” Alok Khorana, MD, said, “but that trial used drug called semuloparin, which is not currently available in the United...
Outpatients Need to Be Aware of High Risk of Developing Venous Thromboembolism
Most patients who develop venous thromboembolisms (VTE) while being treated for cancer, do so as outpatients, according to results of a retrospective, observational study comparing the incidence of VTE among inpatients and outpatients with cancer. Yet many outpatients do not even realize that they...
First Genomic-based Pediatric Trials Launched in Neuroblastoma
Last November, Dell announced it was donating an initial $4 million including cloud-computing technology to speed up development of personalized medicine trials for children with neuroblastoma and other pediatric cancers. According to the American Cancer Society, about 650 children under the age of ...
Shortening the Learning Curve of the U.S. Health-care System
If we are able to harness the full potential of digital technologies, computerized registries, databases, and the Web, could we solve many of the current woes of our sluggish and costly health-care system? Yes, according to Lynn Etheredge, a consultant with the Rapid Learning Project at the George...
Expert Point of View: Therapy for Hodgkin Lymphoma in the Elderly Remains Undefined
Elderly Hodgkin lymphoma, typically defined as affecting individuals ≥ 60 years of age, remains a disease for which no standard treatment recommendation exists. This population is underrepresented in clinical studies, and survival rates in older patients with Hodgkin lymphoma are significantly and ...
Therapy for Hodgkin Lymphoma in the Elderly Remains Undefined
At the 2011 Pan-Pacific Lymphoma Conference held recently in Kauai, Hawaii, Andrew M. Evens, DO, MSc, Director of the Lymphoma Program at the University of Massachusetts Medical School in Worcester, discussed Hodgkin lymphoma in elderly patients. Event-free survival and overall survival rates in...
Advances in Gynecologic Cancer Surgery Continue to Improve Outcomes
Over the past several decades, advances in chemotherapy and surgery have begun to translate into improved survival in gynecologic malignancies. The ASCO Post recently spoke with Ginger Gardner, MD, a surgical oncologist at Memorial Sloan-Kettering Cancer Center, who specializes in the management...
What You Should Know about Denosumab (Prolia) for Increasing Bone Mass during Breast and Prostate Cancer Therapies
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indications In September 2011, the monoclonal antibody RANKL...
Neoadjuvant Chemotherapy or Surgery First: Outcome Not Affected
Chemotherapy can be delivered before breast-conserving therapy or after surgery, without influencing long-term local-regional recurrence, a large study from The University of Texas MD Anderson Cancer Center confirmed. The data were presented at the 2011 Breast Cancer Symposium in San Francisco.1 “A ...
Acupuncture Continues to Secure Position within Integrative Oncology
More than 14 years after an NIH Consensus Panel finding of “efficacy of acupuncture in adult postoperative and chemotherapy nausea and vomiting,” an informal show-of-hands poll at the Eighth International Society for Integrative Oncology (SIO) Conference indicated acupuncture was not yet fully...
NIH Director Calls for Rigorous Evaluation of Integrative Medicine to Provide Evidence of Efficacy
“Many new frontiers exist in integrative medicine,” NIH Director Francis Collins, MD, PhD, stated in his keynote address at the Eighth International Conference of the Society for Integrative Oncology (SIO) in Cleveland. “The evidence is overwhelming that these approaches are being used by many...
‘New Science, New Solutions’ Explored at Society for Integrative Oncology Conference
“Innovating Integrative Oncology: New Science, New Solutions” was the title of the Society for Integrative Oncology (SIO) Eighth International Conference. Topics ranged from molecular biology to mitigation of treatment toxicity to mind-body medicine. A total of 505 people attended the conference,...
Data on Watchful Waiting for Low-risk Prostate Cancer May Swing Focus to Higher-risk Tumors and Quality of Life
Surgery did not increase survival rates compared to watchful waiting in men with clinically localized prostate cancer. Results were particularly strong for men with prostate-specific antigen (PSA) levels of 10 ng/dL and under, and those who have low-risk disease, according to data from the Prostate ...
ODAC Backs Axitinib for Kidney Cancer
The FDA’s Oncologic Drugs Advisory Committee voted 13-0 that Pfizer’s drug axitinib (Inlyta) had a favorable benefit-risk profile for patients with advanced renal cell carcinoma after initial treatment has failed. The FDA is due to make a final decision in the first half of 2012. Panelists said the ...
Resection of Metastatic Lesions Extends Survival in Multiple Tumor Types
Surgical oncologists urged other cancer providers to appreciate the potentially curative role that surgery can play in the management of many stage IV solid tumors, in a session during the American College of Surgeons 97th Annual Clinical Congress in San Francisco. Pulmonary Metastases Stephen G....
Gene Classifier Spots Different Recurrence Patterns in Patients with ER-positive Breast Cancer
A new gene classifier differentiates between women with estrogen receptor (ER)-positive breast cancer who go on to develop metastases early vs late, possibly paving the way for tailored adjuvant therapy. Using pretreatment tumor biopsies, a team led by Minetta C. Liu, MD, of the Georgetown...
SIDEBAR: Bevacizumab in Breast Cancer: Additional Perspective
A recent poll by MDoutlook1 concluded that payer coverage would have a significant role in bevacizumab’s use in metastatic breast cancer. Usage of the drug could be cut by two-thirds in the United States and by one-third outside the United States. The NCCN has kept its recommendation of bevacizumab ...
